Hostname: page-component-6766d58669-nf276 Total loading time: 0 Render date: 2026-05-20T16:52:29.944Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral squamous cell carcinoma and serum paraoxonase 1

Published online by Cambridge University Press:  11 November 2013

Z Boy Metin ,
S Aydin ,
M Unur ,
B Cakmakoglu ,
B Toptas ,
G Hafiz  and
T İsbir
Z Boy Metin
Affiliation:
Department of Oral Surgery and Medicine, Faculty of Dentistry, Istanbul University, Istanbul, Turkey
S Aydin*
Affiliation:
Department of Otorhinolaryngology, Bağcilar Research and Education Hospital, Istanbul, Turkey
M Unur
Affiliation:
Department of Oral Surgery and Medicine, Faculty of Dentistry, Istanbul University, Istanbul, Turkey
B Cakmakoglu
Affiliation:
Department of Molecular Medicine, Institute for Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
B Toptas
Affiliation:
Department of Molecular Medicine, Institute for Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
G Hafiz
Affiliation:
Department of Otolaryngology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
T İsbir
Affiliation:
Department of Molecular Medicine, Institute for Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
*
Address for correspondence: Dr Salih Aydın, Bağcilar Eğitim Araştirma Hastanesi, Kulak Burun Boğaz Kliniği, Bağcilar, Istanbul, Turkey43200 E-mail: drsalihaydin@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Serum paraoxonase 1 is involved in mechanisms that protect cells from oxidative stress damage. This study aimed to investigate the correlation between serum paraoxonase 1 activity and polymorphisms in patients with oral squamous cell carcinoma.

Methods and materials:

Fifty-seven patients with oral squamous cell carcinoma and 59 matched healthy controls participated in the study. Serum paraoxonase 1 activity and polymorphisms in blood samples were compared with results for polymerase chain reaction and restriction fragment length polymorphism tests.

Results:

Mean serum paraoxonase 1 activity levels were lower in patients than controls (mean ± standard deviation, 21.9 ± 5 units/l and 120.4 ± 2 units/l, respectively) (p = 0.001). The serum paraoxonase 1 192 glutamine polymorphism was more common in patients than controls.

Conclusion:

Patients with oral squamous cell carcinoma had significantly lower serum paraoxonase 1 activity levels and a greater prevalence of the serum paraoxonase 1 192 glutamine allele, compared with controls. Serum paraoxonase 1 may play a role in the aetiology of oral squamous cell carcinoma.

Keywords

ParaoxonasePolymorphism, GeneticOral CancerCarcinoma, Squamous CellGenes

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 12 , December 2013 , pp. 1208 - 1213
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Poh, CF, MacAulay, CE, Laronde, DM, Williams, PM, Zhang, L, Rosin, MP. Squamous cell carcinoma and precursor lesions: diagnosis and screening in a technical era. Periodontol 2000 2011;57:73–88CrossRefGoogle Scholar
2Hoffman, HT, Karnell, LH, Funk, GF. The national cancer database report on cancer of head and neck. Arch Otolaryngol Head Neck Surg 1998;124:951–62CrossRefGoogle Scholar
3Funk, GF, Karnell, LH, Robinson, RA, Zhen, WK, Trask, DK, Hoffman, HT. Presentation, treatment, and outcome of oral cavity cancer: a national cancer data base report. Head Neck 2002;24:165–80CrossRefGoogle ScholarPubMed
4Da Silva, SD, Ferlito, A, Takes, RP, Brakenhoff, RH, Valentin, MD, Woolgar, JA et al. Advances and applications of oral cancer basic research. Oral Oncol 2011;47:783–91CrossRefGoogle Scholar
5Sun, Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1990;8:583–99CrossRefGoogle ScholarPubMed
6Fang, DH, Fan, CH, Ji, Q, Qi, BX, Li, J, Wang, L. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep 2012;39:6801–9CrossRefGoogle ScholarPubMed
7Patel, BP, Rawal, UM, Dave, TK, Rawal, RM, Shukla, SN, Shah, PM. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. PS Integr Cancer Ther 2007;6:365–72CrossRefGoogle ScholarPubMed
8Manoharan, S, Kolanjiappan, K, Suresh, K, Panjamurthy, K. Lipid peroxidation and antioxidant status in patients with oral squamous cell carcinoma. Indian J Med Res 2005;122:529–34Google ScholarPubMed
9Subapriya, R, Kumaraguruparan, R, Ramachandran, CR, Nagini, S. Oxidant antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem 2002;35:489–93CrossRefGoogle ScholarPubMed
10Manoharan, S, Baskar, AA, Manivasagam, T, Subramanian, P. Circadian rhythmicity of plasma lipid peroxidation and antioxidants in oral squamous cell carcinoma. Singapore Med J 2005;46:184–8Google ScholarPubMed
11Martínez, C, Molina, JA, Alonso-Navarro, H, Jiménez-Jiménez, FJ, Agúndez, JA, García-Martín, E. Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol 2010;10:71CrossRefGoogle ScholarPubMed
12Costa, LG, Giordano, G, Furlong, CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337–44CrossRefGoogle Scholar
13De Roos, AJ, Gold, LS, Wang, S, Hartge, P, Cerhan, JR, Cozen, W et al. Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:1647–53CrossRefGoogle ScholarPubMed
14Lincz, LF, Kerridge, I, Scorgie, FE, Bailey, M, Enno, A, Spencer, A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 2004;89:628–9Google ScholarPubMed
15Krzystek-Korpacka, M, Boehm, D, Matusiewicz, M, Diakowska, D, Grabowski, K, Gamian, A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes – connection with inflammation. Clin Biochem 2008;41:804–11CrossRefGoogle ScholarPubMed
16Camuzcuoglu, H, Arioz, DT, Toy, H, Kurt, S, Celik, H, Erel, O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009;112:481–5CrossRefGoogle ScholarPubMed
17Antognelli, C, Mearini, L, Talesa, VN, Giannantoni, A, Mearini, E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240–51CrossRefGoogle ScholarPubMed
18Akcay, MN, Polat, MF, Yilmaz, I, Akcay, G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50:225–7Google ScholarPubMed
19Akcay, MN, Yilmaz, I, Polat, MF, Akcay, G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50:273–5Google ScholarPubMed
20Lee, CH, Lee, KY, Choe, KH, Hong, YC, Kim, YD, Kang, JW et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Public Health 2005;38:345–50Google ScholarPubMed
21Stevens, VL, Rodriguez, C, Pavluck, AL, Thun, MJ, Calle, EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2006;15:1226–8CrossRefGoogle ScholarPubMed
22Miller, SA, Dykes, DD, Polesky, HS. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988;16:1215CrossRefGoogle ScholarPubMed
23Adkins, S, Gan, KN, Mody, M, La Du, BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598–608Google ScholarPubMed
24Humbert, R, Adler, DA, Disteche, CM, Hassett, C, Omiecinski, CJ, Furlong, CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993;3:73–6CrossRefGoogle ScholarPubMed
25Furlong, CE, Richter, RJ, Seidel, SL, Costa, LG, Motulsky, AG. Spectrophotometric assay for the enzymatic hydrolysis of the active metabolites of chlorpyrites and parathion by plasma paraoxonase/arylesterase. Anal Biochemistry 1989;180:242–7CrossRefGoogle ScholarPubMed
26Klaunig, JE, Kamendulis, LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239–67CrossRefGoogle ScholarPubMed
27Van Der Logt, EM, Janssen, CH, Van Hooijdonk, Z, Roelofs, HM, Wobbes, T, Nagengast, FM et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005;25:1465–70Google ScholarPubMed
28Lurie, G, Wilkens, LR, Thompson, PJ, McDuffie, KE, Carney, ME, Terada, KY et al. Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:2070–7CrossRefGoogle ScholarPubMed
29Costa, LG, Vitalone, A, Cole, TB, Furlong, CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;15;69:541–50CrossRefGoogle Scholar
30Elkiran, ET, Mar, N, Aygen, B, Gursu, F, Karaoglu, A, Koca, S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48CrossRefGoogle Scholar